Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Seres Therapeutics
Biotech
Seres shrinks head count by 25% to fund biotherapeutic's ph. 2
Seres is laying off a quarter of its workforce as the microbiome biopharma conserves resources to take its infection preventive therapy into phase 2.
James Waldron
Sep 23, 2025 10:00am
Ikena and Inmagene choose combined CEO—Chutes & Ladders
Jul 25, 2025 8:30am
Seres slims R&D, staff to focus on approved microbiome drug
Nov 2, 2023 12:22pm
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
FDA mulls approving first oral microbiome therapy from Seres
Oct 26, 2022 9:55am
Equipped with new safety data, Seres eyes FDA approval
Jun 7, 2022 7:00am
